Retraction
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
Paper Information
Record ID:
39627
Author(s):
Journal:
Publication Date:
February 28, 2010
Retraction Date:
October 06, 2022
(3.1 years years ago)
Subjects:
Institutions:
- Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA
- Wright State University, Dayton, Ohio, USA
- Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio, USA
- Integrated Biomedical Graduate Program, The Ohio State University, Columbus, Ohio, USA
- The Mannheimer Foundation, Inc., Homestead, Florida, USA
Country:
🇺🇸 United StatesArticle Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (696)
696
Total Citations47
Post-Retraction(6.8%)
647
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
4
Within 30 days
20
Within 1 year
9
After 2+ years
967
Days since retraction (latest)
Clinical recommendations: The role of mechanisms in the GRADE framework
Lucie Perillat, Mathew Mercuri
Studies in History and Philosophy of Science Part A
Published: Sep 2022
4 citations
4 citations
19 days before retraction
Mitochondrial Dysfunction in Spinal Muscular Atrophy
Eleonora Zilio, Valentina Piano, Brunhilde Wirth
International Journal of Molecular Sciences
Open Access
Published: Sep 2022
29 citations
29 citations
19 days before retraction
Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect
Haiyan Zhou, Ying Hong, Mariacristina Scoto et al. (22 authors)
Journal of Clinical Investigation
Open Access
Published: Sep 2022
10 citations
10 citations
23 days before retraction
SMN controls neuromuscular junction integrity through U7 snRNP
Sarah Tisdale, Meaghan Van Alstyne, Christian M. Simon et al. (5 authors)
Cell Reports
Open Access
Published: Sep 2022
21 citations
21 citations
35 days before retraction
Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies
Claudia A. Chiriboga
Pediatric Drugs
Published: Aug 2022
12 citations
12 citations
40 days before retraction
The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap
Sharon J. Brown, Rachel Kline, Silvia A. Synowsky et al. (10 authors)
Cells
Open Access
Published: Aug 2022
8 citations
8 citations
44 days before retraction
History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
Jiaying Qiu, Liucheng Wu, Ruobing Qu et al. (8 authors)
Frontiers in Cellular Neuroscience
Open Access
Published: Aug 2022
22 citations
22 citations
55 days before retraction
Progress in spinal muscular atrophy research
Claudia D. Wurster, Susanne Petri
Current Opinion in Neurology
Open Access
Published: Aug 2022
14 citations
14 citations
58 days before retraction
Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA
María J. Carlini, Marina K. Triplett, Livio Pellizzoni
PLoS ONE
Open Access
Published: Aug 2022
7 citations
7 citations
66 days before retraction
Motor defects in a Drosophila model for spinal muscular atrophy result from SMN depletion during early neurogenesis
Stuart J. Grice, Ji‐Long Liu
PLoS Genetics
Open Access
Published: Jul 2022
8 citations
8 citations
73 days before retraction
Newborn Screening for SMA – Can a Wait-and-See Strategy be Responsibly Justified in Patients With Four SMN2 Copies?
Astrid Blaschek, Heike Kölbel, Oliver Schwartz et al. (10 authors)
Journal of Neuromuscular Diseases
Published: Jul 2022
31 citations
31 citations
86 days before retraction
Double administration of self-complementary AAV9<i>NDUFS4</i> prevents Leigh disease in <i>Ndufs4</i>−/− mice
Samantha Corrà, Raffaele Cerutti, Valeria Balmaceda et al. (5 authors)
Brain
Open Access
Published: Jul 2022
11 citations
11 citations
87 days before retraction
Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles
Paladd Asavarut, Sajee Waramit, Keittisak Suwan et al. (12 authors)
EMBO Molecular Medicine
Open Access
Published: Jun 2022
19 citations
19 citations
101 days before retraction
Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
Andrés López‐Cortés, Gabriela Echeverría‐Garcés, María José Ramos-Medina
Biology
Open Access
Published: Jun 2022
11 citations
11 citations
118 days before retraction
A meditation on accelerating the development of small molecule medicines targeting RNA
Xueyi Yang, Jessica L. Childs‐Disney, Matthew D. Disney
Expert Opinion on Drug Discovery
Open Access
Published: Jun 2022
3 citations
3 citations
123 days before retraction
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Drug Design Development and Therapy
Open Access
Published: Jun 2022
42 citations
42 citations
127 days before retraction
Genetic therapeutic advancements for Dravet Syndrome
Ellie Chilcott, Juan Antinao Díaz, Cori Bertram et al. (5 authors)
Epilepsy & Behavior
Open Access
Published: May 2022
40 citations
40 citations
129 days before retraction
Curing SMA: Are we there yet?
Aoife Reilly, Lucia Chehadé, Rashmi Kothary
Gene Therapy
Open Access
Published: May 2022
43 citations
43 citations
133 days before retraction
Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy
Laura H. Comley, Rachel Kline, Alison K. Thomson et al. (8 authors)
Human Molecular Genetics
Open Access
Published: Apr 2022
12 citations
12 citations
163 days before retraction
Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy
Aoife Reilly, Marc‐Olivier Deguise, Ariane Beauvais et al. (10 authors)
Gene Therapy
Open Access
Published: Apr 2022
20 citations
20 citations
164 days before retraction
Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the <i>Smn<sup>2B/-</sup></i> mouse model of SMA
María J. Carlini, Marina K. Triplett, Livio Pellizzoni
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Apr 2022
168 days before retraction
Spinal Muscular Atrophy – Is Newborn Screening Too Late for Children with Two SMN2 Copies?
Oliver Schwartz, Heike Kölbel, Astrid Blaschek et al. (9 authors)
Journal of Neuromuscular Diseases
Open Access
Published: Apr 2022
15 citations
15 citations
174 days before retraction
Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies
Carsten W. Lederer, Lola Koniali, Tina Buerki‐Thurnherr et al. (9 authors)
Pharmaceutics
Open Access
Published: Apr 2022
5 citations
5 citations
184 days before retraction
Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts
Jarichad Toosaranont, Sukanya Ruschadaariyachat, Warasinee Mujchariyakul et al. (10 authors)
International Journal of Molecular Sciences
Open Access
Published: Apr 2022
1 citation
1 citation
188 days before retraction
Pre-symptomatic spinal muscular atrophy: a proposed nosology
Richard S. Finkel, Michael Benatar
Brain
Open Access
Published: Mar 2022
24 citations
24 citations
191 days before retraction
Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives
Ana Fajardo‐Serrano, Alberto J. Rico, Elvira Roda et al. (11 authors)
Biomedicines
Open Access
Published: Mar 2022
8 citations
8 citations
197 days before retraction
Treatment of Adult Spinal Muscular Atrophy: Overview and Recent Developments
Svenja Brakemeier, Benjamin Stolte, Christoph Kleinschnitz et al. (4 authors)
Current Pharmaceutical Design
Published: Mar 2022
4 citations
4 citations
219 days before retraction
Combinatorial Polycation Synthesis and Causal Machine Learning Reveal Divergent Polymer Design Rules for Effective pDNA and Ribonucleoprotein Delivery
Ramya Kumar, Ngoc Le, Felipe Oviedo et al. (5 authors)
JACS Au
Open Access
Published: Feb 2022
44 citations
44 citations
241 days before retraction
Paper citing Rescue of the spinal muscular atrophy phenotype in...
Unknown Authors
Unknown Journal
Published: Feb 2022
241 days before retraction
Gene Therapy for Rare Neurological Disorders
Terence R. Flotte, Dominic J. Gessler
Clinical Pharmacology & Therapeutics
Published: Feb 2022
16 citations
16 citations
247 days before retraction
Brain-wide TVA compensation allows rabies virus to retrograde target cell-type-specific projection neurons
Zengpeng Han, Nengsong Luo, Jiaxin Kou et al. (11 authors)
Molecular Brain
Open Access
Published: Jan 2022
9 citations
9 citations
250 days before retraction
Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
Tejal Aslesh, Toshifumi Yokota
Cells
Open Access
Published: Jan 2022
50 citations
50 citations
253 days before retraction
Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders
Tomoki Hirunagi, Kentaro Sahashi, Katherine G. Meilleur et al. (4 authors)
Genes
Open Access
Published: Jan 2022
11 citations
11 citations
274 days before retraction
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
Sibylle Jablonka, Luisa Hennlein, Michael Sendtner
Neurological Research and Practice
Open Access
Published: Jan 2022
54 citations
54 citations
275 days before retraction
Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
Yujia A. Chan, Benjamin E. Deverman
AAPS advances in the pharmaceutical sciences series
Published: Jan 2022
2 citations
2 citations
278 days before retraction
Treatment for Spinal Muscular Atrophy Using Onasemnogene Abeparvovec
Can Ebru Bekircan‐Kurt, Megan A. Waldrop, Anne M. Connolly et al. (4 authors)
touchREVIEWS in Neurology
Open Access
Published: Jan 2022
278 days before retraction
Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain
Xintao Zhang, Zheng Chai, Amanda Lee Dobbins et al. (9 authors)
Biomaterials
Open Access
Published: Dec 2021
13 citations
13 citations
279 days before retraction
Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases
Giulia Paolini Sguazzi, Valentina Muto, Marco Tartaglia et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Dec 2021
26 citations
26 citations
290 days before retraction
Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets
Kelly Rich, Christopher G. Wier, Jessica Russo et al. (14 authors)
Gene Therapy
Open Access
Published: Nov 2021
8 citations
8 citations
318 days before retraction
Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients
Adrian P. Regensburger, Alexandra L. Wagner, Vera Danko et al. (15 authors)
Photoacoustics
Open Access
Published: Nov 2021
25 citations
25 citations
330 days before retraction
Central and peripheral delivery of AAV9-SMN target different pathomechanisms in a mouse model of spinal muscular atrophy
Aoife Reilly, Marc‐Olivier Deguise, Ariane Beauvais et al. (10 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Nov 2021
1 citation
1 citation
332 days before retraction
Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases
Della Grace Thomas Parambi, Khalid Saad Alharbi, Rajesh Kumar et al. (10 authors)
Molecular Neurobiology
Open Access
Published: Oct 2021
50 citations
50 citations
356 days before retraction
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
Katarzyna Kotulska, Aviva Fattal‐Valevski, Jana Haberlová
Frontiers in Neurology
Open Access
Published: Oct 2021
33 citations
33 citations
358 days before retraction
Transduction profiles in minipig following MRI guided delivery of AAV-5 into thalamic and corona radiata areas
Kimberly L. Pietersz, Stephan M. Pouw, Jiřı́ Klı́ma et al. (19 authors)
Journal of Neuroscience Methods
Published: Oct 2021
360 days before retraction
Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models
Ellie Chilcott, Evalyne W. Muiruri, Theodore C. Hirst et al. (4 authors)
Gene Therapy
Open Access
Published: Oct 2021
9 citations
9 citations
365 days before retraction
Prenatal Gene Therapy
Marisa E. Schwab, Tippi C. MacKenzie
Clinical Obstetrics & Gynecology
Published: Oct 2021
13 citations
13 citations
365 days before retraction
Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes
Yoji Yamada
Cancers
Open Access
Published: Oct 2021
70 citations
70 citations
366 days before retraction
An evaluation of onasemnogene abeparvovec for spinal muscular atrophy (<i>SMN1</i>)
Megan A. Waldrop, Anne M. Connolly, Jerry R. Mendell
Expert Opinion on Orphan Drugs
Published: Oct 2021
368 days before retraction
SLC6A1 and Neuropsychiatric Diseases: The Role of Mutations and Prospects for Treatment with Genome Editing Systems
Е. С. Букина, Nikolay Kondratyev, Sergey V. Kozin et al. (6 authors)
Neurochemical Journal
Published: Oct 2021
1 citation
1 citation
370 days before retraction
Piggybacking on the Cholera Toxin: Identification of a CTB-Binding Protein as an Approach for Targeted Delivery of Proteins to Motor Neurons
Matthew Balmforth, Jess Haigh, Vajinder Kumar et al. (9 authors)
Bioconjugate Chemistry
Open Access
Published: Sep 2021
13 citations
13 citations
374 days before retraction
Quick Stats
Total Citations:
696
Years Since Retraction:
3.1 years
Open Access:
Yes
Last Checked:
Jul 24, 2025